Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,801–1,900 of 2,162
Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma
Latif, T., & John, C. (2013) · InTech eBooks · doi:10.5772/55122 · Cited by 2
Schett, G. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090116
Immunotoxicology in Nonclinical Studies
BURLESON, F. G., & Burleson, S. C. M. (2014) · doi:10.1002/9781118873922.ch22
Unique Considerations for Biopharmaceutics
Andrews, L. P., & Green, J. D. (2010) · Wiley eBooks · doi:10.1002/9780470613191.ch12
Future Pathways for Immune Manipulation
Webber, A. B., & Vincenti, F. G. (2014) · Wiley eBooks · doi:10.1002/9781118873434.ch18
Human mucosal CD4+ T cells but not blood CD4+ T cells respond vigorously towards CD28 engagement
Schröder–Braunstein, J., Pavlov, V., Giese, T., Heidtmann, A., Wentrup, S., Lasitschka, F., Winter, J., Ulrich, A. B., Engelke, A., Saeedi, M. A., et al. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04539.x · Cited by 1
Development of Biological Therapies for Inflammatory Arthritis
Basu, N. (2008) · Springer eBooks · doi:10.1007/978-1-84628-742-8_3
“More recently, the catastrophic cytokine storms that were observed in six healthy volunteers receiving the anti-CD28 antibody TGN1412 have been widely publicized [ 49 ].”
BackgroundRegulatory Review: Clinical to Market Transition
Dallmann, G. (2014) · doi:10.1002/9783527682423.ch42
STUDIES OF CELL SIGNALLING USING BACTERIAL TOXINS AND ORGANIC ELECTRONIC DEVICES
Kjäll, P. (2007) · Figshare
The Early Development of a New Drug
Rosier, J. A., Martens, M. A., & Thomas, J. R. (2014) · doi:10.1002/9781118414873.ch5
Active specific immunotherapy for solid tumors
Baars, A. (2007) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Interferon, Cytokine Induction, and other Potential In Vivo Toxicities
Judge, A. D., Robbins, M., & MacLachlan, I. (2010) · Wiley eBooks · doi:10.1002/9780470923733.ch7
Spicer, J. F., & Bono, J. S. D. (2013) · Wiley eBooks · doi:10.1002/9781118532331.ch13
Chimeric Antigen Receptors – “CARs”
Petrausch, U., & Schirrmann, T. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch20
Profiling Adverse Immune Effects
de Jong, W. H., Pieters, R. H. H., Baken, K. A., Vandebriel, R. J., van der Laan, J. W., & Loveren, H. V. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627448.ch18
Treatment of Heart Failure by Anticytokine Therapies
Vredevoe, D. L., & Gage, J. R. (2007) · doi:10.1002/9780470692325.ch13
"Iatrogenicity cascade": Doing harm by treating harm?
Wagner, C. C., Biollaz, J., Zeitlinger, M. A., & Buclin, T. (2009) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-008-0579-y
Nonclinical Toxicological Support for Phase I Trials
Jones, D. R., & McBlane, J. W. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch8
Co‐Administration of Co‐Stimulatory Moieties
Arancibia-Cárcamo, C. V., & Latchman, Y. E. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch25
Mechanisms of disease and therapy in severe juvenile idiopathic arthritis
Vastert, S. J. (2013) · Utrecht University Repository (Utrecht University)
Immunogenicity and immune function of the cellular prion protein.
Isaacs, J. D. (2007) · UCL Discovery (University College London)
Antigen - presentation by vascular endothelium : its role for CTL - mediated vascular injury
Wang, X. (2008) · edoc (University of Basel) · doi:10.5451/unibas-004696315
Quantitative Multiplexed Patterning of Immune‐Related Biomarkers
Eisinger, D. P., McDade, R. L., & Joos, T. O. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse257
Unravelling disease mechanisms in juvenile dermatomyositis
Elst, E. F. (2007) · Utrecht University Repository (Utrecht University)
Natural CD4+CD25+FOXP3+ regulatory T cells in graft-versus-host disease
Edinger, M., & Hoffmann, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416004-0.00012-4 · Cited by 1
T-Cell Costimulatory Molecules
Sun, Q., & Li, X. C. (2014) · Springer eBooks · doi:10.1007/978-94-017-9472-5_2
Immune Modulators and Other Agents
Charles, E. D., & Jacobson, I. M. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1192-5_11
“In fact the elicitation of near-fatal systemic infl ammatory responses in healthy volunteers who were administered TGN1412, a T-cell activationinducing, superantagonist anti-CD28 mAb [ 1 ] has vividly demonstrated the potential adverse clinical consequences of therapeutic immune system activators.”
BackgroundSuperantigens in group A streptococcus gene diversity and humoral immune response
Maripuu, L. (2011) · DiVA at Umeå University (Umeå University)
Toxicity Data Obtained From Human Studies
Wilks, M. F., & Kupferschmidt, H. (2009) · Wiley eBooks · doi:10.1002/9780470744307.gat046
Biomolecules Versus Smaller Chemicals in Toxicology
Ruthsatz, M., Chiavaroli, C., & Voisin, E. (2014) · Springer eBooks · doi:10.1007/978-3-642-35374-1_57
Comment on “Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis”
Yuan, F., Lü, W., Li, X., Li, J.-P., Li, C.-W., & Xu, R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090115
Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies
Rapoport, A. P., & Ijaz, N. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_9
Modulation of TCR signals reprograms immune tolerance in transplantation and type-1 diabetes
Khattar, M. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Immunotoxicology of Biopharmaceutics
Haggerty, H. G., Price, K., & Shenton, J. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00629-1
Twidell, A., & de Lusignan, S. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511642272.003
Detektion von menschlichen Immunzellen in der humanisierten Maus
Scholbach, J., Köberle, M., Rodewohl, A., et al. (2013) · BIOspektrum · doi:10.1007/s12268-013-0269-1
“[1] Suntharalingam G, Perry MR, Ward S et al.”
Promises and Challenges with Immunomodulatory Biologics
Ponce, R. A. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch8
Monoklonale Antikörper: Grundlagen und ihre Bedeutung in Diagnostik und Therapie
Behrsing, O., & Micheel, B. (2008) · Springer eBooks · doi:10.1007/978-3-540-69414-4_20 · Cited by 1
Role of NK cells in DC-based immunotherapy of melanoma
Bouwer, A. L. (2011) · Otago University Research Archive (University of Otago)
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
“Unfortunately, this trial was terminated due to the signifi cant adverse events seen in a phase I trial of the CD28 mAb TGN1412, which caused life-threatening cytokine storm in treated volunteers [ 113 ].”
BackgroundEstimating the Size of a first dose-The case of a new anti-hypertensive drug (AHD)
(2015) · Precision Medicine · doi:10.14800/pm.993
Monoklonale Antikörper in der Therapie von Tumorerkrankungen
Kripp, M. (2011) · Der Onkologe · doi:10.1007/s00761-011-2074-0 · Cited by 1
Maio, V. (2008) · Population Health Management · doi:10.1089/pop.2008.114802
“7 Also unique to this class of agents is the inherent variability, not only within a class, but from lot to lot.”
Hernández-López, C. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2008.10.022
The role of cytokines in pulmonary edema associated with preterm delivery
Eisenhut, M. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.05.018
Ghosh, S., & Ghosh, R. (2010) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.70934
Update on transplantation tolerance
Cunningham, A. C. (2010) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2010.07.008
Becker, K. J., & Hallenbeck, J. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_16
Commentary on—Michael Eisenhut
Eisenhut, M. (2007) · Journal of Forensic Sciences · doi:10.1111/j.1556-4029.2007.00495.x
Toward a Non-Empirical Treatment for Rheumatoid Arthritis Based on Its Molecular Pathogenesis
Moreno, J. G., Vázquez-Ortíz, G., López-Blanco, J. A., López-Romero, R., & Medina, F. (2008) · Reumatología Clínica (English Edition) · doi:10.1016/s2173-5743(08)70145-x · Cited by 1
T-cell costimulation blockade in immunologic diseases: role of CD28 family members
Clay, B. S., & Sperling, A. I. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.3.383
Role of Potential Immune Targets in Atherosclerosis for Vaccine Development
Venkatesan, N., & Prabhakar, V. R. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00001.x
The 2006 Adrian Salter Lecture1
Breckenridge, A. M. (2007) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200721030-00006
“summer, here in London (if somewhat by happenstance), has been discussed at length in many places.[2,3] It is possible that, in the 2.”
BackgroundÉvaluation critique des traitements non anti-infectieux du sepsis : quelles leçons tirer du passé ?
Montravers, P., Lasocki, S., Séguin, P., et al. (2007) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2007.01.015
The state of the art and the issue of translational research in Japan
Komatsu, H., & Ueda, R. (2007) · Drug Delivery System · doi:10.2745/dds.22.28
The future of biological agents in the treatment of rheumatoid arthritis
Rawlings, C., & Choy, E. (2014) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.14.32 · Cited by 2
Rittner, C. K. (2009) · Legal Medicine · doi:10.1016/j.legalmed.2009.01.018
Perspectives in targeted therapy
Keystone, E. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8238-4_12
Molecular mechanisms in vascular inflammation
Olofsson, P. S. (2008) · Figshare
Building an Integrated Early Clinical Development Platform to Improve the Path to Proof of Concept
Cohen, O. J., & Sax, F. L. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014526600
Mesenchymal Stem/Stromal Cells: Opportunities and Obstacles in ARDS
Curley, G. F., Hayes, M., & Laffey, J. G. (2013) · Springer eBooks · doi:10.1007/978-3-642-35109-9_38
Targeting Cancer Associated Fibroblasts for Cancer Immunotherapy
(2014) · Cancer Cell & Microenvironment · doi:10.14800/ccm.80
“However, these strategies carry the inherent risk of also activating self-reactive T cells, thus restricting their usefulness ([22-24]).”
BackgroundRedirected T cell activity by high affinity TCR-ANTI-CD3 bispecific candidate therapeutics
Adams, K. J. (2013) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
Lymphotoxin-alpha: Another (and better?) therapeutic target in autoimmune disease?
Ey, C., Ivelja, S., Gribling, P., et al. (2009)
Tronconi, M. C., Sclafani, F., Rimassa, L., Carnaghi, C., Personeni, N., & Santoro, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8140
Studies on the immune system in CLL
Mous, R. (2008) · UvA-DARE (University of Amsterdam)
The Evolution of Immunotoxicology*
Luster, M. I. (2014) · doi:10.1002/9783527676965.ch1
Severe Therapy Resistant Asthma in Children
Bush, A. (2009)
Regulatory T cells and immune tolerance after allogeneic hematopoietic stem cell transplantation
Bruinsma, M. (2010) · RePub (Erasmus University Rotterdam)
Lukas, C., Combe, B. G., & Morel, J. (2007) · Future Rheumatology · doi:10.2217/17460816.2.2.143
The Role of Pharmacokinetics and Allometrics in Imaging: Practical Issues and Considerations
Moyer, B. R. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-8247-5_5
Chan, S., Voskens, C., Lin, W., Schindler, D. G., Azimzadeh, A. M., Wang, L., Taylor, R. J., Strome, S. E., & Schulze, D. H. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.937
Review Antibody engineering to develop new antirheumatic therapies
Isaacs, J. D. (2009)
Researchagonistic potential of a candidate therapeutic anti-IL21R antibody
Guo, Y., Hill, A. A. V., Ramsey, R., et al. (2010)
COCERIG ISSUES WITH BIOSIMILARS: AOVERVIEW
Swarna, U. R., Reddy, S., & Bharati, S. (2011)
Major Advances in Pathogenesis, But Not Treatment
Low, D. E. (2013) · Cited by 1
Ein (statistischer) Werkzeugkasten für eine Vorlesung „Klinische Studien“ für Nicht-Statistiker
Ring, A. (2014) · Springer-Lehrbuch · doi:10.1007/978-3-642-54336-4_5
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
Diagnostics and Personalized Medicine
Zanders, E. D. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9902-3_14
Impact of Obesity and Aging on the Tumor Immuno-Environment
Mirsoian, A., Sckisel, G. D., Zamora, A. E., & Murphy, W. J. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_9
Felgate, C. C., Spooner, N., & Calloway, R. (2016) · Bioanalysis · doi:10.4155/bio.15.248
Côté, P.-A. (2007) · Les ateliers de l éthique · doi:10.7202/1044649ar
Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Field, C. S. (2016) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17013761 · Cited by 1
Clinical development of new drugs. Safety of clinical trials in healthy volunteers
Dal‐Ré, R. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.09.025
Patel, B., Gauvin, R., Absar, S., Gupta, V., Gupta, N., Nahar, K., Khademhosseini, A., Ahsan, F., & Gupta (2012)
Prediction of therapeutic index of antibody-based therapeutics: mathematical modeling approaches
Mayawala, K., & Gomes, B. C. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.020
Smith, D. A., & Baillie, T. A. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch3
Animal Models of Transplantation
Issa, F., Hester, J., & Wood, K. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.15017-9
Biologika: „Magic bullets – magic effects – magic costs“? Neue Therapien und ihre (Aus-)Wirkungen
Frey, O., & Kamradt, T. (2011) · Der Ophthalmologe · doi:10.1007/s00347-010-2255-z · Cited by 1
Botturi, K., Lacoeuille, Y., VERVLOET, D., et al. (2012)
Approaches to the Induction of Tolerance
Wood, K. J., & Geissler, E. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00021-8
Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents
Giugliano, R. P. (2009) · Fundamental and clinical cardiology · doi:10.3109/9781420069242.003
Agbeko, R., & Peters, M. J. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-07307-3.10090-4
Rimmele, T. R., Peng, Z., & Kellum, J. A. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814289764_0085
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.